TEL AVIV, Israel, Feb. 01, 2016 (GLOBE NEWSWIRE) -- VBL Therapeutics (NASDAQ:VBLT), announced today that Chief Executive Officer, Dror Harats, M.D., will provide a corporate overview and business update at the BIO CEO & Investor Conference.
|Title:||The 18th Annual BIO CEO & Investor Conference|
|Date:||February 9th, 2016|
|Location:||The Waldorf Astoria New York|
Vascular Biogenics Ltd., operating as VBL Therapeutics, is a late-stage clinical biopharmaceutical company focused on the discovery, development and commercialization of first-in-class treatments for cancer. The company's lead oncology product candidate, VB-111, is a gene-based biologic that is initially being developed for recurrent glioblastoma (rGBM), an aggressive form of brain cancer. VB-111 has received orphan drug designation in both the United States and Europe and was granted Fast Track designation by the FDA for prolongation of survival in patients with glioblastoma that has recurred following treatment with standard chemotherapy and radiation. VBL Therapeutics' pivotal Phase 3 GLOBE trial of VB-111 in rGBM is ongoing under a special protocol assessment granted by the FDA.
INVESTOR CONTACT: Michael Rice, Founding Partner LifeSci Advisors, LLC 646-597-6979
Source: VBL Therapeutics